| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000023040 |
| Receipt No. | R000026555 |
| Official scientific title of the study | The efficacy of intravenous administration of tranexamic acid in curved periacetabular osteotomy |
| Date of disclosure of the study information | 2016/07/10 |
| Last modified on | 2016/07/06 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | The efficacy of intravenous administration of tranexamic acid in curved periacetabular osteotomy | |
| Title of the study (Brief title) | The efficacy of intravenous administration of tranexamic acid in curved periacetabular osteotomy | |
| Region |
|
|
| Condition | ||
| Condition | acetabular dysplasia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is to investigate the evidence for the efficacy of tranexamic acid in reducing blood loss after curve periacetabular osteotomy. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Total Blood loss |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -participants are blinded |
| Control | Dose comparison |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intravenous tranexamic acid 1000mg at the time of incision | |
| Interventions/Control_2 | Intravenous tranexamic acid 1000mg at the time of incision and 1000mg at the time of closure
|
|
| Interventions/Control_3 | control subjects | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | acetabular dysplasia over twenty years of age | |||
| Key exclusion criteria | A history of VTE , renal dysfunction, use of hormone replacement therapy | |||
| Target sample size | 120 | |||
| Research contact person | |
| Name of lead principal investigator | Ayumi Matsunaga |
| Organization | Fukuoka University |
| Division name | Dept.of Orthop.Surg |
| Address | 7-45-1 Nanakuma, Jonan-ku,Fukuoka, Japan |
| TEL | 092-801-1011 |
| matsunaga_s580930@yahoo.co.jp | |
| Public contact | |
| Name of contact person | Ayumi Matsunaga |
| Organization | Fukuoka University |
| Division name | Dept.of Orthop.Surg |
| Address | 7-45-1 Nanakuma, Jonan-ku,Fukuoka, Japan |
| TEL | 092-801-1011 |
| Homepage URL | |
| matsunaga_s580930@yahoo.co.jp | |
| Sponsor | |
| Institute | Fukuoka University,Dept.of Orthop.Surg |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026555 |